Publicaciones en colaboración con investigadores/as de University of California, San Diego (26)

2024

  1. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study

    Hepatology, Vol. 77, Núm. 2, pp. 512-529

2022

  1. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

    npj Parkinson's Disease, Vol. 8, Núm. 1

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 20-30

2020

  1. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

    The Lancet Neurology, Vol. 19, Núm. 1, pp. 71-80

2019

  1. Extracellular Vesicles in Liver Diseases: Meeting Report from the International Liver Congress 2018

    Hepatology Communications, Vol. 3, Núm. 2, pp. 305-315

  2. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

    Parkinsonism and Related Disorders, Vol. 62, pp. 201-209

  3. Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors

    Nature Genetics, Vol. 51, Núm. 5, pp. 804-814

  4. Mechanisms underlying resilience in ageing

    Nature Reviews Neuroscience

  5. Metformin results in diametrically opposed effects by targeting non-stem cancer cells but protecting cancer stem cells in head and neck squamous cell carcinoma

    International Journal of Molecular Sciences, Vol. 20, Núm. 1

2018

  1. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

    Annals of Clinical and Translational Neurology, Vol. 5, Núm. 12, pp. 1460-1477

2016

  1. Immune cell screening of a nanoparticle library improves atherosclerosis therapy

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, Núm. 44, pp. E6731-E6740

2015

  1. Designing a broad-spectrum integrative approach for cancer prevention and treatment

    Seminars in Cancer Biology, Vol. 35, pp. S276-S304

  2. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth

    Nature Communications, Vol. 6

2014

  1. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

    Movement Disorders, Vol. 29, Núm. 4, pp. 470-478

2012

  1. EGFR kinase promotes acquisition of stem cell-like properties: A potential therapeutic target in head and neck squamous cell carcinoma stem cells

    PLoS ONE, Vol. 7, Núm. 2

  2. Expresión de p63 y p73 en neurinomas del acústico y estudio de su posible relevancia clínica

    Acta Otorrinolaringologica Espanola, Vol. 63, Núm. 1, pp. 9-14

  3. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt

    BMC Cancer, Vol. 12